Skip to content
DataLookout
Menu

NCT06048250

Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 4 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 7 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria revised
    • Enrollment closed, study ongoing
    • Primary and study completion pushed from Sep 21, 2026 to Feb 9, 2027
    • Site details revised
  2. Notable Primary and study completion dates: Mar 21, 2026 to Sep 21, 2026v7
  3. Minor Start date changed from estimate of Mar 28, 2024 to Apr 9, 2024v5
  4. Notable Start date: Dec 28, 2023 to Mar 28, 2024v4
  5. Notable Primary and study completion dates: Jul 12, 2025 to Mar 21, 2026
    • Start date: Oct 11, 2023 to Dec 28, 2023
    v3
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of adverse events
Timeframe: Up to 2 years

Secondary (6)

Overall response rate
Complete response rate
Overall survival
Progression free survival
Time to progression
Show 1 moreShow less
Duration of response

Arms and interventions

Treatment (mezigdomide)Experimental

Starting between 30 and 90 days after infusion of idecabtagene vicleucel, patients receive mezigdomide PO on days 1-21 or days 1-14 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo PET/CT during screening. Patients also undergo bone marrow aspiration and blood sample collection throughout the study.

Procedures: Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography, Positron Emission Tomography

Biologicals: Mezigdomide

Sites

1 site in 1 country

  • City of Hope Medical CenterDuarte, California, United States